🇲🇦MoroccoNorth Africa
Morocco faces immunoglobulin supply challenges due to lack of national production
via Le Matin4 min read
A recent tender for immunoglobulin supply to public hospitals in Morocco failed because the financial offer from the sole admitted competitor was deemed excessive. This situation highlights a structural tension in the global immunoglobulin market, exacerbated since the COVID-19 pandemic by increased demand, limited plasma collection capacity, and market concentration among a few industrial players, leading to price surges. The Moroccan Agency of Blood and its Derivatives AMSD and the Ministry of Health aimed to secure supply by structuring the tender into three lots, limiting suppliers to one lot each to avoid dependence on a single operator. Despite these precautions, market realities prevailed. Moroccan health authorities are implementing a multidimensional response to prevent stock shortages, including a national framework for appropriate use to prioritize critical indications, encouraging health establishments to strengthen their own stocks, and accelerating market authorizations for new products, including biosimilars, and facilitating exceptional imports. The AMSD is working to enhance national supply through Moroccan plasma valorization, plasmapheresis development, exceptional imports, and new specialty registrations. While the Ministry assures the availability of safety and strategic reserves, the absence of national immunoglobulin production makes Morocco entirely dependent on imports, exposing it to fluctuations in a concentrated and unstable global market. A nation
Free daily or weekly digest of the most important stories from across 18 African countries. No spam, unsubscribe any time.
This summary was AI-generated from a story originally published by Le Matin.
A new report, the 2026 Labor Force Survey from the HCP, reveals that the Moroccan labor market experiences greater pressure than its 10.8% unemployment rate suggests. The survey indicates that a substantial 22.5% of the workforce is underutilized, a figure that encompasses not only the unemployed but also those who are underemployed and inactive.
Stellantis has launched a new circular economy center in Casablanca. The announcement was made on May 5, 2026, by Le Matin.ma. This initiative aims to promote sustainable practices within the automotive industry.
Morocco's Ministry of Health and Social Protection and AstraZeneca have signed a strategic agreement during the GITEX Future Health Africa - Morocco exhibition. This partnership aims to enhance cooperation in critical areas such as chronic disease screening, the development of digital solutions incorporating artificial intelligence, and the use of real-world data to improve medical decision-making. The agreement also includes strengthening the skills of healthcare professionals and expanding the "Heart Health in Africa" initiative, which focuses on cardiovascular and renal disease management. This collaboration supports Morocco's goal of consolidating its health sovereignty and developing its research and innovation capabilities. Minister Amine Tehraoui noted that Morocco is undergoing a significant transformation of its healthcare system under the Royal Project for the generalization of social protection and universal health coverage. Rami Scandar, AstraZeneca's President for the Middle East and North Africa region, affirmed the group's long-term commitment to Morocco through support for initiatives based on scientific innovation, digital technologies, and artificial intelligence.
Stellantis began 2026 with significantly improved indicators, achieving 38.1 billion euros in revenue, a 6% increase, and returning to a net profit of 0.4 billion euros. This marks a gradual return to profitability after a challenging 2025. The current operating income reached 1 billion euros, with a 2.5% margin, showing notable year-over-year progress driven by improved industrial execution and cost management. Industrial free cash flow remained negative at -1.9 billion euros, partly due to Q1 seasonality and exceptional charges from 2025, but the deficit was reduced by 37%. Stellantis strengthened its financial fundamentals by issuing 5 billion euros in hybrid notes, increasing liquidity to 44.1 billion euros, which is 28% of annual revenue. Commercial performance was generally positive, with North America leading with 6% sales growth, particularly for the Ram brand. Europe also progressed, supported by a diverse offering of thermal, hybrid, and electric powertrains, and maintained leadership in commercial vehicles. South America held its dominant position despite market share erosion, while Asia-Pacific saw a slight decline. The Middle East and Africa region showed resilience with stable sales and improved relative performance in a declining market. Stellantis is focusing on improving quality, production, and customer experience, with new models launched last year contributing to volume increases. The company plans to launch 10 new vehicles and six restyled models in 2026,